B&G Foods Inc. (NYSE:BGS) shares fell -2.44% in last trading session and ended the day at $36.36. BGS Gross Margin is 29.10% and its has a return on assets of 2.70%. B&G Foods Inc. (NYSE:BGS) quarterly performance is 27.80%.
B&G Foods and its subsidiaries manufacture, sell and distribute a diversified portfolio of high-quality, branded shelf-stable foods across the United States, Canada and Puerto Rico. Based in Parsippany, New Jersey, B&G Foods’ products are marketed under many recognized brands, including Ac’cent, B&G, B&M, Baker’s Joy, Bear Creek Country Kitchens, Brer Rabbit, Canoleo, Cary’s, Cream of Rice, Cream of Wheat, Devonsheer, Don Pepino, Emeril’s, Grandma’s Molasses, JJ Flats, Joan of Arc, Las Palmas, MacDonald’s.
B&G Foods, Inc. (NYSE:BGS) announced that its Board of Directors has increased the Company’s quarterly cash dividend rate by 2.9% from $0.34 per share of common stock to $0.35 per share of common stock. On an annualized basis, the dividend increases from $1.36 per share to $1.40 per share. The quarterly dividend declared today is payable on October 30, 2015 to shareholders of record as of September 30, 2015.
Gray Television, Inc. (NYSE:GTN) ended the last trading day at $12.30. Company weekly volatility is calculated as 3.72% and price to cash ratio as 3.98. Gray Television, Inc. (NYSE:GTN) showed a weekly performance of -8.48%.
Gray Television, Inc. (NYSE:GTN and GTN.A) is a television broadcast company headquartered in Atlanta, Georgia, that owns and operates television stations and leading digital assets in markets throughout the United States. Upon the consummation of all announced transactions (including announced divestitures), we will own and/or operate television stations in 49 television markets that broadcast nearly 200 program streams including 35 channels affiliated with the CBS Network, 25 channels affiliated with the NBC Network
On 14 September, it was reported Gray Television, Inc. (NYSE:GTN) announced that it has reached an agreement to acquire all of the television and radio stations of Schurz Communications, Inc. (“Schurz”) for approximately $442.5 million including working capital at closing.
On 28 September, Amicus Therapeutics, Inc. (NASDAQ:FOLD) shares fell -7.18% and was closed at $13.19. FOLD EPS growth in last 5 year was -26.20%. Amicus Therapeutics, Inc. (NASDAQ:FOLD) year to date (YTD) performance is 58.53%.
Amicus Therapeutics (FOLD) is a biotechnology company at the forefront of therapies for rare and orphan diseases. The Company is developing novel, first-in-class treatments for a broad range of human genetic diseases, with a focus on delivering new benefits to individuals with lysosomal storage disorders. Amicus’ lead programs in development include the small molecule pharmacological chaperone migalastat for Fabry disease, as well as next-generation enzyme replacement therapy (ERT) products for Fabry disease, Pompe disease, and MPS I.
On 15 September, Amicus Therapeutics (NASDAQ:FOLD), announced that a Pre-NDA meeting was held with the U.S. Food and Drug Administration (FDA) to discuss the oral small molecule pharmacological chaperone migalastat for the treatment of Fabry disease. The unique mechanism of action of migalastat represents a new personalized medicine option for Fabry patients who have amenable mutations.
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) shares fell -4.62% in last trading session and ended the day at $79.85. ALNY has a return on assets of -14.40%. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) quarterly performance is -30.08%.
Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is leading the translation of RNAi as a new class of innovative medicines. Alnylam’s pipeline of investigational RNAi therapeutics is focused in 3 Strategic Therapeutic Areas (STArs): Genetic Medicines, with a broad pipeline of RNAi therapeutics for the treatment of rare diseases; Cardio-Metabolic Disease, with a pipeline of RNAi therapeutics toward genetically validated, liver-expressed disease targets for unmet needs in cardiovascular and metabolic diseases; and Hepatic Infectious Disease, with a pipeline of RNAi therapeutics that address the major global health challenges of hepatic infectious diseases. In early 2015.
On 15 September, Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), a leading RNAi therapeutics company, announced initial positive results from its ongoing Phase 1 clinical trial with ALN-AS1, an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 (ALAS1) for the treatment of acute hepatic porphyrias. The Phase 1 study is being performed in asymptomatic “high excreter” (ASHE) patients, who carry the genetic mutation of acute intermittent porphyria (AIP) and have elevated levels of aminolevulinic acid (ALA) and porphobilinogen (PBG), the toxic heme intermediates that mediate porphyria attacks.
EndoChoice Holdings, Inc. (NYSE:GI) caters to the Healthcare space. It has a net profit margin of -94.00% and weekly performance is -15.17%. On the last day of trading company shares ended up at $11.69. EndoChoice Holdings, Inc. (NYSE:GI) distance from 50-day simple moving average (SMA50) is -26.43%.
Based near Atlanta, Georgia, EndoChoice (GI) is a medtech company focused on the manufacturing and commercialization of platform technologies including endoscopic imaging systems, devices and infection control products and pathology services for specialists treating a wide range of gastrointestinal conditions, including colon cancer. EndoChoice leverages its direct sales organization to serve more than 2,500 customers in the United States and works with distribution partners in 30 countries.
EndoChoice Holdings, Inc. (NYSE: GI) announced that William (Bill) R. Enquist, former President of Global Endoscopy for Stryker Corporation (SYK), and David (Dave) H. Mowry, President and CEO of Tornier N.V. (TRNX) joined the EndoChoice Board of Directors effective September 9, 2015.
Leave a Reply